A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

被引：0
|
作者：
Anthony W. Tolcher
Leonard J. Appleman
Geoffrey I. Shapiro
Alain C. Mita
Frank Cihon
Arthur Mazzu
Pavur R. Sundaresan
机构：
[1] START (South Texas Accelerated Research Therapeutics),Early Drug Development Center, Department of Medical Oncology
[2] University of Pittsburgh Cancer Institute,Department of Medicine
[3] Dana-Farber Cancer Institute,Clinical Statistics
[4] Brigham and Women’s Hospital,Pharmacodynamics
[5] Harvard Medical School,undefined
[6] Institute for Drug Development,undefined
[7] Cancer Therapy and Research Center,undefined
[8] Bayer Healthcare Pharmaceuticals Inc.,undefined
[9] Bayer Healthcare Pharmaceuticals Inc.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
Cardiovascular adverse event (CAE); Left ventricular ejection fraction (LVEF); Hypertension; QT/QTc interval; Sorafenib; Cardiovascular profile;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：751 / 764
页数：13
相关论文
共 50 条
  • [21] Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors
    Balmana, Judith
    Tung, Nadine M.
    Isakoff, Steven J.
    Grana, Begona
    Ryan, Paula D.
    Rafi, Rezvan
    Tracy, Michael
    Winer, Eric
    Baselga, Jose
    Garber, Judy Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: an open-label, multicenter Phase I study
    Saunders, M.
    Van Cutsem, E.
    Wilson, R.
    Peeters, M.
    Smith, R.
    Godwood, A.
    Oliver, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Nobuaki Matsubara
    Shota Kusuhara
    Noboru Yamamoto
    Kazuki Sudo
    Masahiko Yanagita
    Kosho Murayama
    Hisashi Kawasumi
    Deanna L. Russell
    Da Yin
    Toshio Shimizu
    Cancer Chemotherapy and Pharmacology, 2024, 93 : 341 - 352
  • [24] Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Kondo, Shunsuke
    Iwasa, Satoru
    Koyama, Takafumi
    Fujita, Tomoko
    Sugibayashi, Ko
    Murayama, Kosho
    Yamamoto, Noboru
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (12) : 1795 - 1804
  • [25] Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Shunsuke Kondo
    Satoru Iwasa
    Takafumi Koyama
    Tomoko Fujita
    Ko Sugibayashi
    Kosho Murayama
    Noboru Yamamoto
    International Journal of Clinical Oncology, 2022, 27 : 1795 - 1804
  • [26] Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Matsubara, Nobuaki
    Kusuhara, Shota
    Yamamoto, Noboru
    Sudo, Kazuki
    Yanagita, Masahiko
    Murayama, Kosho
    Kawasumi, Hisashi
    Russell, Deanna L.
    Yin, Da
    Shimizu, Toshio
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (04) : 341 - 352
  • [27] Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors
    Patel, Manish R.
    Falchook, Gerald S.
    Wang, Judy S.
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Miah, Kowser
    Mugundu, Ganesh M.
    Jones, Suzanne F.
    Spigel, David R.
    Hamilton, Erika P.
    TARGETED ONCOLOGY, 2025, 20 (01) : 127 - 138
  • [28] Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label study
    Kondo, Shunsuke
    Katsuya, Yuki
    Yonemori, Kan
    Komuro, Keiko
    Sugeno, Masatoshi
    Kawata, Toshio
    Ghiorghiu, Dana
    Meulendijks, Didier
    Yamamoto, Noboru
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 39
  • [29] Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
    Cheng, Ann-Lii
    Thongprasert, Sumitra
    Lim, Ho Yeong
    Sukeepaisarnjaroen, Wattana
    Yang, Tsai-Shen
    Wu, Cheng-Chung
    Chao, Yee
    Chan, Stephen L.
    Kudo, Masatoshi
    Ikeda, Masafumi
    Kang, Yoon-Koo
    Pan, Hongming
    Numata, Kazushi
    Han, Guohong
    Balsara, Binaifer
    Zhang, Yong
    Rodriguez, Ana-Marie
    Zhang, Yi
    Wang, Yongyu
    Poon, Ronnie T. P.
    HEPATOLOGY, 2016, 64 (03) : 774 - 784
  • [30] Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
    Eisen, T.
    Marais, R.
    Affolter, A.
    Lorigan, P.
    Robert, C.
    Corrie, P.
    Ottensmeier, C.
    Chevreau, C.
    Chao, D.
    Nathan, P. D.
    Jouary, T.
    Harries, M.
    Negrier, S.
    Montegriffo, E.
    Ahmad, T.
    Gibbens, I.
    James, M. G.
    Strauss, U. P.
    Prendergast, S.
    Gore, M. E.
    BRITISH JOURNAL OF CANCER, 2011, 105 (03) : 353 - 359
12345